Difference between revisions of "Pertuzumab (Perjeta)"
| Line 1: | Line 1: | ||
| + | '''In clinical trials''' | ||
==General information== | ==General information== | ||
Class: Humanized monoclonal antibody that binds to subdomain II of HER2, preventing dimerization with other HER receptors, tyrosine kinase activity, and downstream signal cascades. Also stimulates antibody-dependent cell-mediated cytotoxicity.<ref>[http://www.nejm.org/doi/full/10.1056/NEJMoa1113216 CLEOPATRA trial]</ref><ref>[http://www.roche.com/med-cor-2010-12-10 NEOSPHERE trial press release]</ref> | Class: Humanized monoclonal antibody that binds to subdomain II of HER2, preventing dimerization with other HER receptors, tyrosine kinase activity, and downstream signal cascades. Also stimulates antibody-dependent cell-mediated cytotoxicity.<ref>[http://www.nejm.org/doi/full/10.1056/NEJMoa1113216 CLEOPATRA trial]</ref><ref>[http://www.roche.com/med-cor-2010-12-10 NEOSPHERE trial press release]</ref> | ||
Revision as of 20:15, 24 December 2011
In clinical trials
General information
Class: Humanized monoclonal antibody that binds to subdomain II of HER2, preventing dimerization with other HER receptors, tyrosine kinase activity, and downstream signal cascades. Also stimulates antibody-dependent cell-mediated cytotoxicity.[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.
Patient drug information
No information available.